– USA, MA – Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, announced the appointment of Dr. Tunde Bello (Ph.D.) to its board of directors.
“Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,” said Board chair, Paul Clancy. “With over 25 years of experience in oncology research and development, focused on translational medicine and clinical pharmacology at BMS and Pfizer, we look forward to benefitting from Tunde’s extensive expertise as we advance toward the clinic with XTX501, our masked PD-1/IL-2 bi-specific, and our bi-specific and tri-specific masked T cell engager programs.”
About Dr. Akintunde Bello, Ph.D.
Dr. Tunde Bello brings more than 25 years of oncology drug development and leadership experience to Xilio, with deep expertise in early translational medicine and clinical pharmacology across complex biologics and immunotherapies, including anti-CTLA-4 and PD-1 checkpoint inhibitors, T cell engagers, and tumor-selective molecules. He most recently served as SVP, head of clinical pharmacology, pharmacometrics, and bioanalysis at Bristol Myers Squibb Company until his retirement in 2025. While at BMS, Dr. Tunde Bello oversaw clinical pharmacology and pharmacometrics across multiple therapeutic areas. Before BMS, he spent more than a decade with Pfizer Inc., where he was responsible for overseeing clinical pharmacology for Pfizer’s late-stage oncology development programs.
“Xilio’s innovative approach to developing tumor-activated immuno-oncology therapies presents an exciting opportunity to advance novel molecules, which hold the potential to overcome the limitations of current cancer treatments,” said Dr. Tunde Bello. “I am honored to join Xilio’s board of directors at this important time and look forward to contributing to Xilio’s efforts to meaningfully improve outcomes for patients while minimizing systemic toxicities.”
Dr. Tunde Bello received a B.Sc. in biomedical sciences from Portsmouth Polytechnic, an M.Sc. in instrumentation and analytical science from the University of Manchester, and a Ph.D. in pharmaceutical sciences from King’s College, University of London.
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies to significantly improve outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment.
For more: https://xiliotx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.